Oakworth Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Oakworth Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.7K	Sell	124 -125	-50%	-$55.4K	﹤0.01%	432
2026 Q1	$111K	Buy	249 +135	+118%	+$63K	0.01%	344
2025 Q4	$51.7K	Sell	114 -108	-49%	-$46.6K	﹤0.01%	429
2025 Q3	$86.9K	Buy	222 +58	+35%	+$24.2K	0.01%	366
2025 Q2	$73K	Sell	164 -3	-2%	-$1.38K	﹤0.01%	328
2025 Q1	$81K	Hold	167	–	–	0.01%	318
2024 Q4	$67.3K	Hold	167	–	–	﹤0.01%	333
2024 Q3	$77.7K	Buy	167 +25	+18%	+$12K	0.01%	319
2024 Q2	$66.6K	Buy	+142	New	+$61.6K	﹤0.01%	310
2023 Q2	–	Sell	-38	Closed	-$12K	–	653
2023 Q1	$12K	Hold	38	–	–	﹤0.01%	419
2022 Q4	$11K	Hold	38	–	–	﹤0.01%	412
2022 Q3	$11K	Hold	38	–	–	﹤0.01%	436
2022 Q2	$11K	Hold	38	–	–	﹤0.01%	439
2022 Q1	$10K	Hold	38	–	–	﹤0.01%	453
2021 Q4	$8K	Hold	38	–	–	﹤0.01%	507
2021 Q3	$7K	Hold	38	–	–	﹤0.01%	502
2021 Q2	$8K	Buy	+38	New	+$7.95K	﹤0.01%	492
2020 Q3	–	Sell	-14	Closed	-$4K	–	619
2020 Q2	$4K	Buy	+14	New	+$3.8K	﹤0.01%	499

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Oakworth Capital's VRTX Position: Q2 2026 in Review

Oakworth Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 50% in Q2 2026, selling an estimated $55.4K and leaving 124 shares worth $61.7K. The position accounts for ﹤0.01% of the portfolio, ranked #432.

Oakworth Capital first reported a position in VRTX in Q2 2020 and has held it in 18 quarters since. The position peaked at $111K in Q1 2026. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Oakworth Capital held 124 shares of Vertex Pharmaceuticals worth $61.7K as of Q2 2026.
Oakworth Capital sold 125 Vertex Pharmaceuticals shares in Q2 2026, an estimated $55.4K.
Vertex Pharmaceuticals made up ﹤0.01% of Oakworth Capital's portfolio in Q2 2026, its #432 holding.
Oakworth Capital first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
Oakworth Capital's Vertex Pharmaceuticals position peaked at $111K in Q1 2026.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Oakworth Capital's 13F filing for Q2 2026, filed 22 Jul 2026.